Vaxchora

Phase 3Small molecule

UUniversity of Maryland, Baltimore

Vaxchora is one of 3 small molecule programs targeting Typhoid. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TyphoidRecruiting

TyphoidPhase 3

Recruiting

Competition

Competitive Landscape

2 competitors in Typhoid

#DrugCompanyPhaseTrials

Vivotif Typhoid Oral Vaccine

UUniversity of Maryland, Baltimore

Phase 3

1 2

Vaxchora

UUniversity of Maryland, Baltimore

Phase 3

1 3

Salmonella Typhimurium

MMasonic Cancer Center, University of Minnesota

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

ApprovedRecruiting

Typhoid

NCT03705585

Clinical

Trials by Indication[1]

Donor1 trial

Blood Donor CVD 9000

Terminated·UUniversity of Maryland, Baltimore·Phase 4·NCT03724357·3 enrolled

Immunogenicity1 trial

VAXCHORA Pediatric Study to Assess Safety and Immunogenicity

Completed·BBavarian Nordic·Phase 4·NCT03220737·550 enrolled

Vaccine1 trial

Immunologic Responses to a Live Attenuated Oral Cholera Vaccine

Completed·EEmory University·Phase 2·NCT03251495·34 enrolled

Typhoid1 trial

CVD 38000: Immunity, Microbiome, Epigenetics, and a Systems Biology Approach to the Study of Responses to Vaccination With Typhoid and/or Cholera

Recruiting·UUniversity of Maryland, Baltimore·Approved·NCT03705585·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Vaxchora. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vaxchora compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vaxchora. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Maryland, Baltimore company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Maryland, Baltimore

Vaxchora

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Donor1 trial

Immunogenicity1 trial

Vaccine1 trial

Typhoid1 trial

References

Drug Info

Quick Facts

Related News